Legend Biotech Announces Closing Of License Transaction For Certain CAR-T Therapies Targeting DLL3; Under Terms, Co. Will Receive $100M Upfront Cash Payment
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech has completed a licensing deal for CAR-T therapies targeting DLL3. The company will receive an upfront cash payment of $100 million as part of the agreement terms.
January 03, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech has closed a licensing transaction for its CAR-T therapies targeting DLL3, receiving a substantial $100 million upfront payment.
The closing of this licensing transaction is significant for Legend Biotech as it provides a substantial cash payment of $100 million, which is likely to have a positive impact on the company's financial position in the short term. This influx of cash could be used to further research and development, potentially leading to positive investor sentiment and an increase in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100